Affiliation:
1. Rostov State Medical University
Abstract
Objective: to evaluate changes in the activity of markers of pro/antioxidant systems of liver tissue of animals carrying melanoma B16 with the introduction of dimethyltin bis (3,5-di-tert-butyl-4-hydroxyphenylthiolate) (Me-3) at different stages of the development of the tumor process.Materials and methods: the study was conducted on mice of the C57Bl/6 line (females). 48 hours after the transplantation of tumor cells to female mice of the C57Bl/6 line, the studied compounds were administered intraperitoneally 1 time per day for 5 days according to the classical method used for screening compounds with a suspected antitumor effect. The tested compounds were administered at a total dose of 375 mg/kg. The animals were removed from the experiment on the 7th and 18th days after the transplantation of tumor cells.Results: with the introduction of Me-3, there was a decrease in malondialdehyde as the main indicator of the activity of lipid peroxidation at all stages of the development of the tumor process.Conclusions: the multidirectional effect of Me-3 on the enzymatic activity of the antioxidant system on days 7 and 18 of the development of melanoma B16 suggests some selectivity of action depending on the initial pro/antioxidant status of the cell, as well as the expediency of studying this group of compounds as a substrate for nanozymes with pro/antioxidant activity.
Publisher
Rostov State Medical University
Reference22 articles.
1. Syed Annuar SN, Kamaludin NF, Awang N, Chan KM. Cellular Basis of Organotin(IV) Derivatives as Anticancer Metallodrugs: A Review. Front Chem. 2021 Jul 23;9:657599. doi: 10.3389/fchem.2021.657599.
2. Dodokhova M.A., Safronenko A.V., Kotieva I.M., Sukhorukova N.V., Gantsgorn E.V., Alkhuseyn-Kulyaginova M.S., Komarova E.F., Shpakovsky D.B., Milaeva E.R.
3. Pharmacotherapeutic potential’s evaluation of organotin compounds in vivo // Russian Journal of Biopharmaceuticals. 2021. V. 13. N 3. Pp. 30-34.
4. Attanzio, A., D’Agostino, S., Busà, R., Frazzitta, A., Rubino, S., Girasolo, M. A., et al. (2020). Cytotoxic Activity of Organotin(IV) Derivatives with Triazolopyrimidine Containing Exocyclic Oxygen Atoms. Molecules 25 (859), 1–16. doi:10.3390/molecules25040859
5. Tabassum, S., and Pettinari, C. (2006). Chemical and Biotechnological Developments in Organotin Cancer Chemotherapy. J. Organomet. Chem. 691, 1761–1766. doi:10.1016/j.jorganchem.2005.12.033